HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.